221 related articles for article (PubMed ID: 21404002)
1. FGF23 in skeletal modeling and remodeling.
Lu Y; Feng JQ
Curr Osteoporos Rep; 2011 Jun; 9(2):103-8. PubMed ID: 21404002
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization.
Liu S; Gupta A; Quarles LD
Curr Opin Nephrol Hypertens; 2007 Jul; 16(4):329-35. PubMed ID: 17565275
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 23 and its receptors.
Yu X; White KE
Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D and type II sodium-dependent phosphate cotransporters.
Kido S; Kaneko I; Tatsumi S; Segawa H; Miyamoto K
Contrib Nephrol; 2013; 180():86-97. PubMed ID: 23652552
[TBL] [Abstract][Full Text] [Related]
5. Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting.
Bacchetta J; Bardet C; Prié D
Metabolism; 2020 Feb; 103S():153865. PubMed ID: 30664852
[TBL] [Abstract][Full Text] [Related]
6. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.
Goldsweig BK; Carpenter TO
Curr Osteoporos Rep; 2015 Apr; 13(2):88-97. PubMed ID: 25620749
[TBL] [Abstract][Full Text] [Related]
7. [FGF23 and skeletal metabolism].
Michigami T
Clin Calcium; 2014 Jun; 24(6):879-84. PubMed ID: 24870839
[TBL] [Abstract][Full Text] [Related]
8. [Disorders of phosphate metabolism].
Fukumoto S
Rinsho Byori; 2010 Mar; 58(3):225-31. PubMed ID: 20408440
[TBL] [Abstract][Full Text] [Related]
9. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
Stubbs J; Liu S; Quarles LD
Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
[TBL] [Abstract][Full Text] [Related]
10. Overview of the FGF23-Klotho axis.
Kuro-o M
Pediatr Nephrol; 2010 Apr; 25(4):583-90. PubMed ID: 19626341
[TBL] [Abstract][Full Text] [Related]
11. FGF23 and Bone and Mineral Metabolism.
Fukumoto S
Handb Exp Pharmacol; 2020; 262():281-308. PubMed ID: 31792685
[TBL] [Abstract][Full Text] [Related]
12. Phosphate-sensing and regulatory mechanism of FGF23 production.
Takashi Y; Fukumoto S
J Endocrinol Invest; 2020 Jul; 43(7):877-883. PubMed ID: 32140858
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model.
Nakatani T; Ohnishi M; Razzaque MS
FASEB J; 2009 Nov; 23(11):3702-11. PubMed ID: 19584304
[TBL] [Abstract][Full Text] [Related]
14. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
15. Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23.
Fukumoto S
Intern Med; 2008; 47(5):337-43. PubMed ID: 18310961
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.
Wöhrle S; Henninger C; Bonny O; Thuery A; Beluch N; Hynes NE; Guagnano V; Sellers WR; Hofmann F; Kneissel M; Graus Porta D
J Bone Miner Res; 2013 Apr; 28(4):899-911. PubMed ID: 23129509
[TBL] [Abstract][Full Text] [Related]
18. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders.
Bai X; Miao D; Li J; Goltzman D; Karaplis AC
Endocrinology; 2004 Nov; 145(11):5269-79. PubMed ID: 15284207
[TBL] [Abstract][Full Text] [Related]
19. Increased osteopontin contributes to inhibition of bone mineralization in FGF23-deficient mice.
Yuan Q; Jiang Y; Zhao X; Sato T; Densmore M; Schüler C; Erben RG; McKee MD; Lanske B
J Bone Miner Res; 2014 Mar; 29(3):693-704. PubMed ID: 24038141
[TBL] [Abstract][Full Text] [Related]
20. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone.
Sitara D; Kim S; Razzaque MS; Bergwitz C; Taguchi T; Schüler C; Erben RG; Lanske B
PLoS Genet; 2008 Aug; 4(8):e1000154. PubMed ID: 18688277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
